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Abstract 
Background Superﬁcial fungal infections are common. It is important to conﬁrm the clinical diagnosis by mycological laboratory 
methods before initiating systemic antifungal treatment, especially as antifungal sensitivity and in vitro sus- ceptibility may differ 
between different genera and species. For many years, the gold standard for diagnosis of superﬁcial fungal infections has been 
direct fungal detection in the clinical specimen (microscopy) supplemented by culturing. Lately, newer molecular based methods 
for fungal identiﬁcation have been developed. 
Objective This study was initiated to focus on the current usage of mycological diagnostics for superﬁcial fungal infec- tions by 
dermatologists. It was designed to investigate whether it was necessary to differentiate between initial diagnos- tic tests and 
those used at treatment follow-up in speciﬁc superﬁcial fungal infections. 
Methods An online questionnaire was distributed among members of the EADV mycology Task Force and other der- matologists 
with a special interest in mycology and nail disease. 
Results The survey was distributed to 62 dermatologists of whom 38 (61%) completed the whole survey, 7 (11%) par- tially 
completed and 17 (27%) did not respond. Nearly, all respondents (82–100%) said that ideally they would use the result of direct 
microscopy (or histology) combined with a genus/species directed treatment of onychomycosis, der- matophytosis, Candida- and 
Malassezia-related infections. The majority of the dermatologists used a combination of clinical assessment and direct 
microscopy for treatment assessment and the viability of the fungus was considered more important at this visit than when 
initiating the treatment. Molecular based methods were not available for all responders. Conclusion The available diagnostic 
methods are heterogeneous and their usage differs between different practices as well as between countries. The survey 
conﬁrmed that dermatologists ﬁnd it important to make a mycological diagno- sis, particularly prior to starting oral antifungal 
treatment in order to conﬁrm the diagnose and target the therapy accord- ing to genus and species. 
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Introduction 
Superficial fungal infections are common mycoses with clinical 
manifestations that depend on the anatomical site involved and 
the type of fungus causing the infection. 
Although the clinical picture of the different infections is 
characteristic, it is important to confirm the diagnosis by 
mycological laboratory methods before initiating systemic 
antifungal treatment, especially as  antifungal  sensitivity  and  
in vitro susceptibility may differ between different genera and 
species. Furthermore, a Canadian study has proved that mak-   
ing a mycological diagnosis prior to topical and  oral  treat-  
ment is cost  saving.1 
For many years, the gold standard for diagnosis of superficial 
fungal infections has been direct microscopy often performed 
by the clinician, and culture sometimes supplemented by 
histopathology. Since the first dermatophyte polymerase chain 
reaction (PCR) was developed in 19962 an array of new molecu- 
lar based methods for fungal identification have been 
developed with different PCR techniques and lately, matrix 
assisted laser desorption/ionization – time of flight (MALDI-
TOF) mass spec- trometry has also been used.3–10  Because 
special equipment     is required to perform molecular 
diagnostics the analysis is per- formed at specialized 
mycological or microbiological laborato- ries. Unfortunately, 
the molecular methods used differ between laboratories and 
the methods are often ‘in-house’ and have not been 
standardised for cross comparison. Some of the molecular 
based methods only detect dermatophytes and relevant fungi 
such  as  Candida,  Malassezia  and  non-dermatophyte   
moulds such as Neoscytalidium is not detected whereas other    
methods detect all fungi, including fungi which are not clinically 
relevant, leaving it to the clinician to decide whether the result 
is  relevant 
for the clinical diagnosis or due to contamination. An overview 
of the current available diagnostic methods including the pros- 
and cons is shown in Table 1. 
Another important issue is that the clinician is involved in 
diagnostic mycology in two clinical settings, which require 
different diagnostic approaches. The first scenario is when the 
clinician suspects a fungal infection and wants this confirmed 
before initiation of treatment and the mycological  diagnosis  
may provide a guide to the appropriate choice of antifungal 
treatment. The other clinical scenario occurs at the follow-up 
visit where an assessment of treatment efficacy, including 
clearance of infection, or persistence is evaluated. These two 
settings require different mycological diagnostic procedures 
which most of the molecular diagnostic methods are not  
designed to cover. 
This study was initiated to focus on the current usage of 
mycological diagnostics for superficial fungal infections by der- 
matologists about both the optimal tests and what they 
actually use in their daily current practice. It was designed to 
investigate whether it was necessary to differentiate between 
initial diagnos- tic tests and those used at treatment follow-up 
in specific super- ficial    fungal    infections;    onychomycosis,   
dermatophytosis, Candida- and Malassezia-related infections. 
 
Methods 
An online English questionnaire was distributed among mem- 
bers of the EADV mycology Task Force and other dermatologists 
with a special interest in mycology and nail disease. 
The questionnaire focused on the use of diagnostic methods  
to confirm a fungal infection as well as the subsequent assess- 
ment of treatment. It was divided into questions  regarding     
the 
Table 1  The advantages and disadvantages of available diagnostic methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
participants views on the optimal diagnostic techniques, their 
actual use of locally available diagnostic methods and prioritisa- 
tion of those methods they considered to be the most 
important in order. They were asked to differentiate between 
diagnostic requirements in specific clinical settings; 
onychomycosis, Malas- 
sezia related diseases (pityriasis versicolor, Malassezia  folliculi- 
tis), dermatophytosis (tinea capitis, tinea of other skin sites) 
and superficial yeast infections. 
 
Results 
An online survey was distributed to 62 dermatologists of whom 
38 (61%) completed the whole survey, 7 (11%) partially com- 
pleted the questionnaire and 17 (27%) did not respond. Some 
of these non-responders later replied, that they had not 
provided answers either because they were histopathologists 
or only spe- cialised in general nail disorders and were 
therefore not able to answer questions about specialised 
dermatomycology. The mean age of the participants was 54.5 
years (range 31–88 year). The majority of the responders 
worked in Europe [Belgium (n =   2), 
Bosnia   (n = 1),   Denmark   (n = 3),   Estonia   (n = 1),  France 
(n = 3), Greece (n = 3), Germany (n = 2), Iceland (n = 1), Italy (n = 
1), Latvia (n = 1), Poland (n = 1), Portugal (n = 2), Rus-  sia (n = 
1), Spain (n = 2), Sweden (n = 2), Switzerland (n = 2), The  
Netherland  (n = 3),  Turkey  (n = 2),  United  Kingdom   (n = 3)] 
and fewer from Asia [India (n = 1), Japan (n = 1), Korea (n = 1), 
Philippines  (n = 1)]  or  the  Americas  [Brazil  (n = 3), USA (n = 
1)]. A total of 60% of the dermatologists  were employed  in 
public hospitals  and 40%  worked  in private 
practice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nails – when onychomycosis is suspected (n = 40 completed the 
survey, ﬁve partially completed) 
 
Before initiation of treatment When onychomycosis is sus- 
pected 91% of those asked opted as the ideal diagnostic tests 
for direct microscopy to confirm the diagnosis and 67% also 
required the differentiation between yeast, dermatophyte and 
non-dermatophyte mould to (i) genus (58%) or (ii) species  
(53%) level (Table 2a, Fig. 1). One third of the dermatologists 
stated that ideally the clinically suspicion of nail infection should 
be confirmed by histology too but only 13% were interested in 
knowing if there was only a single fungus isolated or whether it 
was viable. The most important pieces of diagnostic informa- 
tion, in order, were considered by the responders to be identifi- 
cation to species level (24%), differentiation between yeasts, 
dermatophyte and non-dermatophyte moulds (22%), diagnosis  
at genus level (18%), direct microscopy (18%), histology (11%), 
viability of the fungus (4%) and the presence of a single culture 
(2%). In their daily practice, 90% of the responders used cul- 
ture, 95% performed direct microscopy, 37% histology whereas 
only 27% used a molecular based method (Table 2b). Six of the 
dermatologists stated that they performed PCR when the 
culture results were negative or a mould was cultured [e.g. 
Mucor spp. (where there is a risk of overgrowth of the 
dermatophyte due to its faster growth rate)]. It was also 
suggested by some of the responders that an in vitro 
susceptibility test should be per- formed when the isolated 
fungus was known to have a variable susceptibility profile. 
Histology was suggested, when the diagno- sis    of    infection    
was    doubtful.    One    dermatologist used 
Detect 
viability 
Pros Cons Other comments 
Direct 
microscopy 
in KOH 
No Conﬁrms the presence of any fungus 
Fast 
Cost-effective 
Not genus or species speciﬁc Fluorescence microscopy enhances 
the detection rate 
Culture Yes Detects unexpected pathogens 
Raises the conﬁrmation chance in case of 
Time consuming (days – weeks) 
Dependent on growth media 
  negative microscopy Requires skilled lab. technicians 
  Permits elective antifungal  
  susceptibility testing  
Histopathology No Conﬁrms the presence of the Not genus or species speciﬁc 
  fungus in the tissue Expensive 
Molecular 
based 
methods 
No Fast (hours – days) 
Detects both viable and non-viable fungal 
material and provides identiﬁcation to genus 
Pre-deﬁned diagnostic target No standardization 
Contamination risk 
  and species level  
  Not dependent on laboratory technicians skills  
  Requires small amount of material  
Woods light No Fast Not species speciﬁc 
  Inexpensive  
  Good for screening  
  Tinea capitis: genus differentiation  
  Guide the clinician to the optimal sampling area  
 
  
 
 
 
 
 
 
 
 
 
Table 2 (a) Diagnostic consideration and treatment decision making among dermatologists. (b) Methods used among dermatologist before and after treatment 
 
 
*The clinical response is the main assessment parameter. 
D, dermatophyte; ID, Identiﬁcation; M, non-dermatophyte mould; Y, yeast. 
Before: before treatment initiation. Follow-up: treatment assessment. 
Minimum diagnostic information 
needed before treatment initiation 
Onychomycosis Tinea capitis Tinea of the skin* Superﬁcial 
Candidasis* 
Pityriasis versicolor* Malassezia 
folliculitis 
 % (n/total) % (n/total) % (n/total) % (n/total) % (n/total) % (n/total) 
(a)       
Fungus detected in the specimen (Direct 
microscopy and/or histology) 
91% (41/45) 97% (38/39) 89% (34/38) 82% (31/38) 89% (34/38) 92% (35/38) 
Genus/species directed treatment 98% (44/45) 82% (32/39) ND 100%(38/38) 18% (7/38) 34% (13/38) 
Differentiation between Y, D & M 67% (30/45) NA NA NA NA NA 
ID to genus level 58% (26/45) 67% (26/39) 53% (20/38) 42% (16/38) 13% (5/38) 29% (11/38) 
ID to species level 53% (24/45) 64% (25/39) 58% (22/38) 58% (22/38) 13% (5/38) 21% (8/38) 
Pattern of resistance 2% (1/45) ND ND 24% (9/38) 0% (0/38) 0% (0/38) 
Woods light ND 51% (16/39) 3% (1/38) ND 21% (8/38) 21% (8/38) 
Histology 33% (15/45) 13% (5/39) 16% (6/38) ND 0% (0/38) 24% (9/38) 
       
       
(b)             
Direct 
microscopy 
95% (39/41) 75% (30/40) 92% (36/39) 79% (31/39) 95% (36/38) 58% (22/38) 82% (31/38) 42% (16/38) 87% (33/38) 47% (18/38) 87% (33/38) 45% (17/38) 
Histology 37% (15/41) 15% (6/40) 13% (5/39) 5% (2/39) 3% (1/38) 3% (1/38) 3% (1/38) 5% (2/38) 0% (0/38) 0% (0/38) 16% (6/38) 8% (3/38) 
Culture 90% (37/41) 73% (29/40) 69% (27/39) 72% (28/39) 58% (22/38) 34% (13/38) 68% (26/38) 37% (14/38) 16% (6/38) 3% (1/38) 26% (10/38) 5% (2/38) 
Molecular 
diagnostic 
27% (11/41) 8% (3/40) 18% (7/39) 3% (1/39) 16% (6/39) 0% (0/39) 8% (3/38) 0% (0/38) 16% (6/38) 0% (0/38) 5% (2/38) 3% (1/38) 
Woods light ND ND 41% (16/39) 44% (17/39) 16% (6/39) 5% (2/39) ND 3% (1/38) 37% (14/38) 3% (1/38) 21% (8/38) 21% (8/38) 
Viability 
important 
13% (6/45) 88% (35/40) 21% (8/39) 82% (32/39) ND 53% (20/38) ND 39% (15/38) ND 32% (12/38) ND 37% (14/38) 
Susceptibility 
test 
ND ND ND ND ND ND 16% (6/38) 3% (1/38) 0% (0/38) 0% (0/38) 0% (0/38) 0% (0/38) 
. 
 
 
Diagnostic 
tests in every 
day use 
Onychomycosis Tinea capitis  Tinea of the skin* Superﬁcial Candidasis* Pityriasis versicolor* Malassezia folliculitis 
Before % 
(n/total) 
Follow-up % 
(n/total) 
Before % 
(n/total) 
Follow-up % 
(n/total) 
Before % 
(n/total) 
Follow-up % 
(n/total) 
Before % 
(n/total) 
Follow-up % 
(n/total) 
Before % 
(n/total) 
Follow-up % 
(n/total) 
Before % 
(n/total) 
Follow-up 
% (n/total) 
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Genus/species directed treatment 
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biopsy. The users of PCR preferred this method because it is 
very fast, so that treatment can start nearly immediately. 
 
Treatment assessment The majority of the  dermatologists  used 
a combination of clinical assessment, Woods light (44%) and 
direct microscopy (79%) and/or culture (72%). A few reported 
that they used molecular diagnostic methods (3%) and 
histology (5%; Table 2b). Half of the participants stated that 
culture was the most important diagnostic method (51%), fol- 
lowed by direct microscopy (36%) and only a few dermatologists 
would choose a molecular based method (5%), histology   (3%), 
Figure 1 The percentage of dermatologists who consider direct fungal 
detection in the specimen (microscopy and/or histology) and 
genus/species directed treatment as sufﬁcient before treat- ment 
initiation in superﬁcial dermatomycoses. MF, Malassezia folliculitis; 
O, onychomycosis; PV, pityriasis versicolor; 
TC, tinea capitis; SC, superﬁcial Candidiasis. 
and other (unspecified; 5%) if they had to choose between the 
methods. 
 
Skin – when dermatophytosis is suspected (n  =   38) 
   Before  initiation  of  treatment   When  a  tinea  (dermatophyte) 
infection of the skin was suspected the majority of the dermatol- 
ogists would like the diagnosis confirmed by direct   microscopy 
dermoscopy of the nail (onychoscopy) as a guide to initiating 
treatment when the clinical suspicion was strong, but direct 
microscopy with KOH was negative, because culture normally 
takes 3–4 weeks. 
 
Treatment assessment The dermatologists consulted evalu- ated 
the treatment efficacy by clinical judgement of the nor-   mal 
regrowth of the proximal  nail.  As  a  diagnostic  test  culture 
(73%) was still the most popular method as it also confirms if 
the fungus is viable, which a total of 88% stated       to be 
important. Direct microscopy was  performed  by  75%  and 
histology and/or a molecular based diagnostic method by 15% 
and 8%, respectively. (Table  2b). 
 
Hair – when tinea capitis is suspected (n = 39) 
 
Before initiation of treatment The majority of all respondents 
said that ideally they would use the result of direct microscopy 
before starting treatment (97%; Table 2a) except those who 
had access to molecular diagnostic tests (3%). Half of the 
dermatolo- gists said that they would use Woods light to 
differentiate between Trichophyton and Microsporum species 
and 21% said that it was important to know if the fungus was 
viable before starting treatment. Only 13% suggested 
histopathology to con- firm or exclude a diagnosis. In their daily 
practice, they used direct microscopy (92%), culture (69%), 
Woods light (41%), molecular diagnostics (18%) and histology 
(13%; Table 2b). If they had to choose between the diagnostic 
methods 38% would use direct microscopy, 57% the 
identification of the organism to genus and/or species level 
using specific diagnostic methods and 5% wanted to know 
whether the fungus was viable or make a 
(89%) and fungal identification to genus (53%) and/or species 
level (58%; Table 2a). The most important diagnostic tool was 
considered to be direct microscopy (45%), followed by culture 
(29%), a molecular based method (11%) or clinical evaluation 
(16%). When it came to what was used in practice 95% used 
direct microscopy, 58% culture, 16% a molecular based method 
and 16% made the diagnosis based upon Woods light and clini- 
cal appearance. Only a few used histology (3%; Table 2b). 
 
Treatment assessment Nearly, all (95%) used clinical evalua- tion 
combined with direct microscopy (58%), culture (34%), Woods 
light (5%) or histology (3%). Approximately half (53%) said that 
it was important to know if the fungus was viable (Table 2b). 
 
Malassezia related skin diseases (n = 38) When 
pityriasis versicolor (PV) is suspected 
 
Before initiation of treatment The clinical picture was rated as the 
main criterion for diagnosis, but for confirmation direct 
microscopy was the main (89%) diagnostic tool (Table 2a). A 
few clinicians wanted a genus and/or species specific (18%) diag- 
nostic method, 21% used Woods light and 3% used a molecular 
based method (Table 2a). 
When asked to choose between the methods 74% stated 
that direct microscopy was the most important diagnostic 
method, 11% the clinical appearance of the patient, 8% culture 
result, 5% Woods light and 3% molecular diagnostic method. In 
practice, the majority used direct microscopy (87%) followed by 
Woods light (37%), culture  (16%),  molecular  diagnostics  
(16%;  Table 2b). 
P
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Treatment assessment The majority of  dermatologists  said that 
the clinical signs of PV were the most important for confirming 
treatment efficacy (92%) and 47% used direct microscopy, 3% 
culture, 3% Woods light for treatment assessment (Table 2b). 
The majority (71%) of the responders said, that if they had to  
prioritize  between  the  diagnostic  tools, direct microscopy 
was the most important  tool  fol-  lowed by the clinical 
appearance  (13%),  culture  (11%),  Woods light (3%), and  
molecular  based  diagnostics  (3%).  One third stated that it 
was important to know if the fungus     was viable. 
 
When Malassezia folliculitis is suspected (n = 38) 
 
Before initiation of treatment For diagnosis of Malassezia folli- 
culitis, 92% of dermatologists wanted direct microscopy of the 
specimen. Genus/and/or species identification was suggested 
by 34%, histology by (24%), Woods light (21%) and molecular 
diagnostics (8%; Table 2a). If they could choose between the 
methods the majority would use direct microscopy (32%), fol- 
lowed by clinical appearance (29%), culture (18%), histology 
(16%). Some of the dermatologists stated that clinical 
diagnostic features including distribution and presence of 
itching was also important and histology was suggested to rule 
out  other  diseases. 
 
Treatment assessment The clinical response was used by 87% to 
evaluate the treatment, 45% also used direct  microscopy, 21%  
Woods  light,  and   fewer   histology   (8%),   culture   (5%) or 
molecular diagnostics (3%;  Table 2b).  Most  (63%)  did not 
consider assessing the viability of the fungus impor-  tant. 
 
Skin/mucosa – when a yeast (Candida) infection is 
suspected (n = 38) 
 
Before initiation of treatment Most dermatologists ideally 
required a microscopy  result  (82%),  or  identification  to  
genus (42%) and/or species (58%) level before initiating ther- 
apy and/or susceptibility testing (24%; Table 2a). The  speci- 
men is sometimes sent to a specialist mycology laboratory, as 
many non-specialist laboratories will not identify Candida to 
species level. 
The responders were asked to choose the most important 
diagnostic information they needed before treatment initiation 
and the results were in order, species identification (47%), 
direct microscopy (42%) and genus identification (11%). In 
practice, direct microscopy was used by 82%, culture (68%), 
susceptibil- ity test (16%), and a molecular based method (8%; 
Table 2b). Clinical appearance (8%) and histology (3%) is used 
more  rarely. 
Treatment assessment All dermatologists evaluated the patient 
clinically, supplemented by direct microscopy (42%), culture 
(37%), histology (5%), susceptibility test (3%) and Woods light 
(3%; Table 2b). Some stated, that susceptibility testing might be 
necessary in cases of treatment failure. 
 
Discussion 
The development of new molecular diagnostic methods for 
iden- tification of fungal infections has resulted in many new 
diagnos- tic opportunities, but it also places a higher demand 
on the skills of the dermatologist/clinician. If these methods 
detect all fungal material (Panfungal) the clinician has to be 
able to distinguish between primary pathogens, colonizing fungi 
and contaminants for example by microscopy. It is also 
important that the clinician knows the limitations of the 
methods for example a dermato- phyte PCR will not detect non-
dermatophyte moulds or yeast. The answers by the group 
showed that, at present, molecular tools are not widely used 
for diagnosis of superficial mycoses although all recognised that 
this situation was likely to change with further simplification of 
the methods and the adoption of this methodology across a 
wider range of microbiology/mycol- ogy laboratories. 
The majority of dermatologists wanted to confirm the fun-   
gal diagnosis before treatment initiation by direct microscopy 
(82–100%) as well as identification to genus or species level 
(82–100%) except in Malassezia related  infections,  where  
direct microscopy was thought to be sufficient for fungal 
identification. In the future this may present a challenge for   
both clinical diagnosis and training in dermatology because 
direct microscopy is regarded as a point of care test, in other 
words a test used by the clinician  in clinic,  and therefore  for 
the foreseeable future, training  in  direct  microscopy  along  
with other tests which can be deployed in the clinic such as 
dermoscopy should form part of the training requirements for 
dermatologists. 
This goal of mycological confirmation before treatment ini- 
tiation was much higher  than that  reported  in previous  stud-  
ies where only 47–60% of dermatologists, 47% of podiatrists  
and 22% of family practitioners said that they confirmed the 
clinical diagnosis of onychomycosis by a mycological   test.11–13 
A high false negative detection rate when combining direct 
microscopy and culture in onychomycosis as well as the slow 
fungal growth may have led to this lower result. The develop- 
ment of molecular based methods, which are fast and have a 
higher detection rate than conventional methods may be one      
of the reasons for this as 27% of the dermatologist in this sur-  
vey used a molecular based method.14 Other reasons might be 
that  in  many  societies  evidential  documentation  before 
treat- 
ment initiation is important for legal or re-imbursement  rea- 
sons. Finally, the responders of this survey are experts in 
mycology    and    therefore    committed    to    establishing      a 
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mycological result, and the results of this study may therefore 
differ from routine diagnosis in general   practice. 
In onychomycoses, the  use  of  systemic  antifungal  therapy 
is common and many of the dermatologists stated, that the 
planned choice between topical or systemic treatment  may  
affect their preference of diagnostic methods. If the clinician 
considers topical monotherapy appropriate, the clinical find-  
ings are often regarded as sufficient (lower risk  of  side-  
effects), but before starting oral treatment, mycological con- 
firmation of diagnosis is required.  Another  important  issue  
that did not form part of the survey but was highlighted by   
some in the free comments section is in vitro susceptibility 
testing which is used to detect acquired resistance after anti- 
fungal treatment. Unfortunately, susceptibility testing is not 
available  for  all  clinicians  even  though  terbinafine 
resistance 
has been detected in T. rubrum, T. mentagrophytes and T. in- 
terdigitale15–17 and antifungal resistance is considered to be a 
growing global problem 
In this survey, viability of the infecting organism is con- 
sidered important in treatment assessment as a  positive  cul- 
ture would prolong the duration of the  treatment  course  or  
lead to a change in anti-mycotic treatment. This is the main 
reason why molecular based diagnostics were not used as a 
diagnostic  tool  in  treatment  assessment.  The  incorporation  
of a viability-test as well as identifying molecular markers of 
drug resistance in any future battery of molecular diagnostic  
tests would extend  the  use  of  these  techniques.  In  support  
of this half of the dermatologists surveyed stated that it is 
important to make a species specific diagnosis in cases of 
recurrent  or  treatment  resistant  infections  especially  in  
Can- 
dida  infections  as  organisms  such  as  C. glabrata  and  C. kru- 
sei  are  known to  have  a lower  susceptibility  to fluconazole.18 
 
Conclusion 
The survey reflects the fact that the available diagnostic meth- 
ods are heterogeneous and their usage differs between differ-   
ent practices as well as between countries. Nevertheless it 
confirmed that dermatologists find it important to make a 
mycological investigation, particularly prior to starting oral 
treatment in order to confirm the diagnosis  of  fungal  infec- 
tion and target the therapy according to genus and species.  
When it comes to treatment assessment the clinical response 
combined with species identification, assessment of  viability 
and susceptibility testing are considered important. Molecular 
based methods are useful in establishing the  diagnosis,  but  
their role in treatment assessment  is  still  limited  as  they  
detect both viable and non-viable fungal elements. The future 
development of methods being able to bridge this current gap 
would be welcome. These findings have training implications  
for the next generation of   dermatologists 
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